u/DaveHervey

🤖 ANALYSIS

Most expeditious realistic timeline
(assuming zero delays and maximum pressure under the Executive Order)

• September 2, 2026
  ALJ issues and serves the recommended decision in favor of moving marijuana to Schedule III.

• September 22, 2026
  20-calendar-day window for parties to file exceptions closes.

• September 27, 2026
  Earliest possible date the ALJ can certify the complete record to the DEA Administrator (regulations set a hard floor of no sooner than 25 days after service).

• September 27–28, 2026
  Administrator issues the final order adopting the ALJ recommendation “as soon as practicable.” With the Executive Order pushing for the fastest process and the agency’s prior speed on the medical portion, this could happen the same day or the next business day the certified record arrives.

• September 29 – October 1, 2026
  Final order is sent to the Office of the Federal Register. Under priority handling it can appear on public inspection within 1–2 days and be formally published around October 1—the fastest plausible window.

Effective date

• Standard rule (21 CFR § 1308.45): no earlier than 30 days after publication → earliest ~October 31.
• Most expeditious path: Administrator invokes the public-health-or-safety exception (the same authority used for the April 2026 medical order that took effect on the publication date). In that case the rule could take effect on the publication date itself or within a few days.

Bottom line for the absolute fastest track
ALJ recommendation on September 2 → record certified September 27 → final order + Federal Register publication by ~October 1 → effective immediately or within days under the health/safety exception.

This puts full Schedule III status for the broader category of marijuana in early October 2026 at the earliest. Any slowdowns (normal 30-day effective date, review delays, or litigation stays) push it into late October or November.

TDR - The Dales Report

🇺🇸🧺 $MSOS 🟢 5.31%

🌎🧺 $YOLO 🟢 4.23%

🍄🧺 $PSIL 🟢 .15%

⚕️ $CWBHF 🟢 9.27%

🇺🇸 $TSNDF 🟢 8.38%

🇨🇦 $TLRY 🟢 8.05%

🇨🇦 $DBCCFF 🟢 7.96%

🇨🇦 $ROMJF 🟢 7.34%

🇺🇸 $CURLF 🟢 6.96%

🇺🇸 $VEXTF 🔴 1.43%

🇮🇱 $INCR 🔴 2.11%

🌱$GRWG 🔴 2.17%

🇨🇦 $AVTBF 🔴 3.56%

Every quarter, someone asks why a cannabis company owns twenty-one beer brands.

Tilray’s latest numbers just made the question impossible to ignore: beverage revenue nearly matching cannabis, with weed now down to just 25% of the business. The easy answer is diversification. The real one is far more interesting—and it has nothing to do with hops.

Aug 19, 2026 Anthony Varrell, TDR

Every quarter, someone asks why a cannabis company owns twenty-one beer brands.

Tilray's fiscal 2026 numbers made the question louder: beverage revenue of $254.0 million against cannabis revenue of $268.3 million, with cannabis down to 29% of the company — and just 25% in Q4.

The conventional read is diversification. Cannabis got hard, beer was for sale, Irwin Simon likes deals. That's not wrong, but it misses what's actually being assembled. Look at the asset list and one thing keeps appearing that has nothing to do with beer.

What Tilray actually owns

The portfolio is now genuinely large. SweetWater, Montauk, Shock Top, Breckenridge Brewery, Breckenridge Distillery, Blue Point, 10 Barrel, Redhook, Widmer Brothers, Alpine, Green Flash, Terrapin, Atwater, Hop Valley, Revolver, Square Mile Cider, Hi*Ball Energy, Casa Breck, Liquid Love, Mock One, Mountain Shot.

The build ran in three waves. SweetWater in 2020, then Montauk, Alpine and Green Flash. Then the eight-brand Anheuser-Busch package in 2023 — Shock Top, Breckenridge, Blue Point, 10 Barrel, Redhook, Widmer, Square Mile, Hi*Ball — which vaulted Tilray from ninth to fifth largest craft brewer in America. Then the 2024 Molson Coors transaction, which brought more brands plus, notably, Mollo and XMG, Canadian THC beverage brands.

And in March 2026, BrewDog — £33 million for worldwide IP, UK brewing operations and eleven brewpubs, followed weeks later by the US assets: the Columbus, Ohio brewery, pubs in Columbus, New Albany, Cleveland and Las Vegas, plus a hotel.

Simon's framing on BrewDog is the tell. He described acquiring world-class brewing infrastructure and strategic real estate at a fraction of the capital and time to build it, noting the Ellon brewing operation alone represents over £100 million of invested capital — and adding that Tilray is not entering Europe from scratch, not leasing capacity, not testing distribution relationships market by market.

Read that sentence again and substitute "THC beverages" for "beer." It works perfectly.

The thing beer buys that cannabis can't

Here's the strategic core. In the United States, alcohol moves through a three-tier system: producers sell to licensed distributors, distributors sell to licensed retailers. Those distributor relationships are the single hardest asset to acquire in beverages. They take decades to build, they're governed by state franchise laws that make them nearly impossible to terminate, and they determine which products get cold-box placement in every grocery, convenience store, bar and stadium in America.

Cannabis companies have no access to that system. State-licensed cannabis moves through state-licensed dispensaries, period. A Curaleaf or a Green Thumb can build the best THC beverage in the country and it will never touch a Kroger shelf.

Tilray, by owning five of the largest craft beer brands in America, sits inside that system. It has TTB permits, it has distributor agreements in all fifty states, it has retail relationships, it has brewery infrastructure that can produce non-alcoholic and functional beverages, and it has brewpubs and taprooms — controlled on-premise venues.

That is not a beer strategy that happens to look useful for cannabis. That's an option on federal beverage policy, purchased with beer cash flow.

Where Van Duyne changes everything

Which brings us to the Beverage Regulatory Parity Act, introduced August 10 by Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH).

The bill would exempt hemp beverages from the November recriminalization and instead regulate them through the TTB, HHS and USDA, permitting adults 21 and over to buy drinks containing up to 5 milligrams of total intoxicating THC per serving — defined as a 12-ounce single-serve container or a 750ml multi-serve bottle. It imposes a federal excise tax of 8 cents per milligram of intoxicating THC, mandates testing, packaging, labeling and advertising requirements, bans synthetic cannabinoids, and lets states impose stricter rules or prohibit outright.

And critically: it establishes a three-tier distribution system modeled directly on alcohol.

If that passes, the competitive landscape reorganizes overnight. THC beverages stop being a dispensary product and become an adult beverage category — permitted by TTB, distributed by the same wholesalers who move Bud Light, sold anywhere beer is sold.

Now ask who is positioned for that.

Tilray would need essentially nothing new. It already holds TTB permits. It already has the wholesaler agreements. It already owns brewing and canning capacity across Georgia, Colorado, New York, Oregon, Ohio and Scotland. It already operates brewpubs that could pour THC beverages on-premise. And through Mollo and XMG, it already has THC beverage brands with Canadian formulation and production experience.

The MSOs would need to build all of it, and mostly couldn't — a plant-touching operator can't hold a TTB permit while trafficking a Schedule I or III substance federally.

The honest caveats Three.

The bill is one of several competing proposals, none of which has yet gained traction with congressional leadership. The Senate's continuing resolution moved the ban to December 11; the House hasn't acted.

Tilray's beverage business is not itself a profit machine. Fiscal 2026 produced a $105.2 million net loss and negative $69.1 million in operating cash flow. The optionality is real; the current returns are thin.

And the 5mg cap plus 8 cents per milligram creates a low-dose, taxed category — closer to seltzer economics than dispensary economics.

The read

Tilray spent six years and hundreds of millions buying its way into the American three-tier system under the cover of a craft beer roll-up. If Van Duyne-Landsman becomes law, that looks less like diversification and more like the best-timed regulatory arbitrage in the industry.

If it doesn't, Tilray owns a mid-sized craft brewer in a declining category. The beer was never the point. The shelf was.

TDR Newsletter

Wed, August 19, 2026 at 5:05 a.m. MDT 6 min read

ACB +1.94%

Curaleaf's decision to launch a hostile takeover bid is designed to pressure Aurora's shareholders into a short-term decision for the benefit of Curaleaf shareholders.

Curaleaf's actions and comments reflect its objective: to acquire, at the lowest price possible, Aurora's market-leading EU-GMP facilities and global medical cannabis platform.

Curaleaf's description of Aurora's business performance does not reflect our recently reported quarterly results and stated European medical cannabis strategy.

Comments by Curaleaf's CEO failed to present the facts; Aurora has engaged with Curaleaf since June 2026, including as recently as August 12, 2026.

Questions about the Offer or would like to stay informed? Please contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or at contactus@kingsdaleadvisors.com.

EDMONTON, AB, Aug. 19, 2026 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, confirmed that Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF), has commenced an unsolicited take-over bid for all of the issued and outstanding common shares of the Company (the "Aurora Shares") at a stated implied consideration of US$4.00 per Aurora Share, consisting of 0.3463 subordinate voting shares of Curaleaf plus US$0.75 in cash per Aurora Share (the "Offer"). We note that the Offer includes a cap on the value of the consideration of US$5.00 per Aurora Share, which is a lower price than Aurora Shares have traded as recently as December 18, 2025.

Miguel Martin, Executive Chairman and CEO of Aurora stated, "The strong shareholder support demonstrated at our 2026 AGM reinforces our commitment to the long-term strategy we are executing. We believe Curaleaf made a strategic decision to make its offer public to pressure our shareholders into making a short-term decision for the benefit of Curaleaf shareholders. We will not do that. We are building this Company for the long term and will always do what is right for Aurora shareholders."

"Contrary to assertions by Curaleaf, our door is always open to those that see value in our Company. Aurora has been in dialogue with Curaleaf going back to June 22, 2026 and as recently as August 12, 2026. Their objective is to acquire Aurora's highly strategic EU-GMP facilities and leading medical cannabis platforms at the lowest price possible, thereby depriving Aurora shareholders of any current and future value they generate," concluded Mr. Martin.

The Offer follows an announcement by Curaleaf on August 11, 2026 of its intention to make an offer for Aurora. At that time, Aurora confirmed that it received letters from Curaleaf dated June 23, 2026, and July 7, 2026, outlining proposals to acquire the Aurora Shares. The June 23, 2026, letter contained no proposed financial terms and the July 7, 2026, letter included no detail regarding the mix of cash and share consideration being proposed by Curaleaf.

The Company expects to provide a more comprehensive response to Aurora shareholders in a timely manner.

Take No Action on Offer

Aurora shareholders are advised to take NO action on the Offer until the Board of Directors of Aurora (the "Board") has made a formal recommendation to shareholders. The Offer will remain open for a minimum of 105 days, allowing Aurora shareholders until at least December 1, 2026 to consider their options.

The Board has formed a special committee of independent directors (the "Special Committee"). The Special Committee will consider the Offer with its advisors before making a recommendation to the Board. Aurora shareholders will be notified of the Board's formal recommendation through a news release and Directors' Circular within 15 days, in accordance with applicable securities laws.

Advisors

Aurora has retained the following leading industry advisors:

Legal counsel to Aurora's Special Committee is Torys LLP.

Legal counsel to the Company are Stikeman Elliott LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP.

Fort Capital Partners is the Company's financial advisor and ICR is the Company's communications counsel.

Kingsdale Advisors is the Company's strategic advisor and information agent.

Shareholder Assistance

Aurora shareholders with questions about the Offer or who would like to stay informed may contact Kingsdale Advisors, the Company's strategic advisor and information agent:

Toll-Free (within North America): 1-800-749-9052 Call or Text: 416-623-4172 Email: contactus@kingsdaleadvisors.com

Shareholders should take NO action at this time. Shareholders should wait until the Board has provided its formal recommendation regarding the Offer.

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Aug 18, 2026

As a global medical cannabis leader, Tilray Medical supports continued policy development that strengthens physician confidence, protects patient access and provides a clear, sustainable framework for medical cannabis in Germany.

The guidance issued by the KBV and GKV-Spitzenverband represents an important step forward by providing greater practical direction for the prescribing of standardized full-spectrum cannabis extracts. Tilray Medical welcomes this progress and encourages policymakers to build upon it with legislative clarity that provides physicians, patients, healthcare providers and payers with a consistent and durable framework for medical cannabis care.

DENSBORN, Germany, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc.(“Tilray”) (Nasdaq: TLRY; TSX: TLRY), considers the recent guidance issued by the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) on the prescription of medical cannabis in the form of standardized full-spectrum extracts a step in the right direction. Important legal and regulatory questions nevertheless remain unresolved under Germany’s revised framework for reimbursed medical cannabis prescribing. Durable legal certainty for physicians, patients, healthcare providers and payers will ultimately require legislative clarification.

Rajnish Ohri, President, International, Tilray Brands, said, “The guidance represents meaningful progress and provides valuable direction for healthcare professionals navigating medical cannabis prescribing. Continued legislative clarity will help strengthen confidence in the framework and support long-term stability for patients, physicians and healthcare providers.”

Practical Clarity from the KBV and GKV-Spitzenverband Guidance

The current interpretation issued by the KBV and the GKV-Spitzenverband provides important practical clarity for healthcare professionals and patients. It represents a constructive step toward safeguarding patient access to treatment and creating a more predictable prescribing framework.

Mr. Ohri, added, “Germany continues to set an important example for medical cannabis in Europe by advancing a thoughtful, science-based framework that puts patients and physicians at the center of care. Tilray Medical is committed to working with physicians, regulators and industry partners to help strengthen confidence in Germany’s medical cannabis system and ensure patients have access to the therapies that best meet their needs.”

Remaining Legal and Regulatory Questions

First, physicians require greater certainty regarding the appropriate use of cannabis-based therapies, including standardized full-spectrum extracts and other magistral preparations. Practical guidance and access to a broad range of pharmaceutical-quality cannabis medicines remain essential to ensuring that treatment decisions are driven by clinical need and patient outcomes. The principle that finished medicinal products should be trialed only within their approved indication, and that ineffective or poorly tolerated therapies should not be unnecessarily prolonged, supports sound medical practice and protects physician autonomy.

Second, continuity of care must remain a priority for patients already benefiting from cannabis-based treatment. Patients stabilized on standardized full-spectrum extracts or other magistral preparations should be protected from avoidable treatment disruptions. Regulatory certainty is necessary so that therapeutic decisions remain focused on individual patient needs. Administrative uncertainty should not determine the course of a treatment.

Third, as reimbursement rules continue to evolve, all stakeholders would benefit from greater predictability regarding treatment pathways and reimbursement eligibility. Patients, physicians, health insurers and healthcare providers need a stable statutory framework that supports responsible access and consistent implementation throughout the healthcare system.

The Case for Legislative Clarification

Tilray Medical supports a clear statutory framework that protects physicians’ freedom of therapy and safeguards continuity of care for existing patients. Such a framework would also provide greater predictability regarding reimbursement and treatment pathways. Codifying these principles in legislation would reduce implementation uncertainty and ensure sustainable patient access to appropriate therapies.

Mr. Ohri, continued, “The current guidance represents meaningful progress. Building on this progress through additional legislative clarity and codifying this interpretation in law would preserve physicians’ freedom of therapy and maintain a predictable reimbursement framework. It would also give patients, healthcare providers and health insurers the long-term planning reliability they need.”

Strengthening Physician Decision-Making

Tilray Medical believes physicians need practical guidance and access to a broad range of pharmaceutical-quality cannabis medicines. The clarification that finished medicinal products should be trialed only within their approved indication, and that ineffective or poorly tolerated treatments should not be prolonged, supports sound clinical judgment and helps avoid unnecessary disruption for patients already stable on standardized full-spectrum extracts or other magistral preparations.

Supporting a Responsible Transition for Patients

With reimbursement changes affecting cannabis flower, patients should have timely access to appropriate alternatives, including standardized full-spectrum extracts. Through its cultivation, manufacturing and distribution operations in Germany, supported by its global medical cannabis platform and quality standards, Tilray Medical is well positioned to support the market responsibly while helping ensure reliable access for patients and healthcare providers.

Supporting Germany Through a Reliable Medical Cannabis Platform

Tilray Medical supports continued collaboration among policymakers, physicians, regulators and industry leaders as Germany advances its medical cannabis system. With international scale, a broad product portfolio and deep operating experience, Tilray Medical is well positioned to help shape the next phase of responsible cannabis care in Germany and across Europe.

Tilray Medical’s presence in Germany reflects years of investment in a reliable, integrated medical cannabis platform. The Company holds a leading position in Germany’s medical cannabis oil market, with 45% market share, supported by cultivation and manufacturing capabilities in Germany and Portugal, including its Aphria RX facility and the ARX brand developed for German patients. Through CC Pharma, Tilray also reaches approximately 16,000 pharmacies and major wholesalers, helping support access to high-quality medical cannabis products for physicians and patients across Germany. With this foundation in Germany, Tilray Medical is helping define a more reliable, physician-led path for medical cannabis care.

About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama.

$TilrayArmy💰🍀-

For every short seller selling $TLRY💰🍀:

You can keep investing in the stock, but you can’t ignore the underlying reality.

Tilray just posted record fiscal 2026 revenue of $915.5 million, record adjusted EBITDA of $61.1 million, and reduced net debt to virtually ZERO — just $0.7 million. Q4 revenue rose 25% to $281.7 million, while Q4 adjusted EBITDA hit a record $31.9 million. Management is targeting another FY2027 EBITDA growth of $68-75 million. (Yahoo Finance⁠)

And while you’re trying to crush the stock price, the cannabis regulatory landscape is moving in the opposite direction. The Trump administration has pushed through federal cannabis reform/rescheduling, creating a potentially massive structural catalyst for the entire sector.

So let’s be honest about what’s happening:

You’re not destroying Tilray’s business. You’re destroying its stock price. There’s a huge difference. The company is growing its revenue. EBITDA is growing. The balance sheet has improved dramatically. Cannabis reform is approaching a potential turning point. And yet, the stock continues to trade as if Tilray is on the verge of collapse.

At some point, fundamentals catch up with positioning.

Short sellers can create fear.

They can create volatility.

They can manipulate sentiment.

But they can’t permanently prevent the recognition of improving fundamentals. Keep shorting if you want. Just remember: every short position must be closed eventually.

And when the market finally decides that $TLRY💰🍀 is worth valuing based on its actual business, balance sheet, and emerging cannabis-related opportunity, rather than on perpetual fear - the exit door may suddenly become very, very small.

OVI @OVI_USA posted on X